keyword
https://read.qxmd.com/read/38252907/nivolumab-plus-chemotherapy-in-epidermal-growth-factor-receptor-mutated-metastatic-non-small-cell-lung-cancer-after-disease-progression-on-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-final-results-of-checkmate-722
#21
JOURNAL ARTICLE
Tony Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Wu, Justin Gainor, Se-Hoon Lee, Chao-Hua Chiu, Sang-We Kim, Cheng-Ta Yang, Chien Liang Wu, Lin Wu, Meng-Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih-Hsin Yang
PURPOSE: The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251) evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal growth factor receptor ( EGFR )-mutated metastatic non-small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs). METHODS: Patients with disease progression after first- or second-generation EGFR TKI therapy (without EGFR T790M mutation) or osimertinib (with/without T790M mutation) were randomly assigned 1:1 to nivolumab (360 mg once every 3 weeks) plus platinum-doublet chemotherapy (once every 3 weeks) or platinum-doublet chemotherapy alone (once every 3 weeks) for four cycles...
January 22, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38241818/efficacy-of-immune-checkpoint-inhibitors-for-metastatic-colorectal-cancer-with-microsatellite-instability-in-second-or-latter-line-using-synthetic-control-arms-a-non-randomised-evaluation
#22
JOURNAL ARTICLE
Romain Cohen, Morteza Raeisi, Benoist Chibaudel, Takayuki Yoshino, Qian Shi, John R Zalcberg, Richard Adams, Chiara Cremolini, Axel Grothey, Robert J Mayer, Eric Van Cutsem, Josep Tabernero, Hideaki Bando, Toshihiro Misumi, Michael J Overman, Thierry André, Aimery de Gramont
PURPOSE: Immune checkpoint inhibitors (ICIs) appeared active in single-arm trials for patients with chemoresistant metastatic colorectal cancer (mCRC) harboring microsatellite instability (MSI). Given the paucity of randomised controlled trials (RCTs) in this setting, we evaluated the effect size of ICIs using intra-patients comparison and ARCAD database as historical controls. PATIENTS AND METHODS: Individual-patient data from NIPICOL and CheckMate 142 phase II trials that evaluated a combination of ICIs for MSI mCRC patients (N = 176) and from five non-ICI mCRC historical RCTs in second-line or latter (N = 4026) were analyzed...
March 2024: European Journal of Cancer
https://read.qxmd.com/read/38230590/nivolumab-in-squamous-cell-carcinomas-of-the-head-and-neck-scchn-a-real-world-outcome-study-in-ontario-canada
#23
JOURNAL ARTICLE
Arman Zereshkian, Ruaa Shafi, Gregory R Pond, Sebastien J Hotte
The CheckMate-141 trial led to the approval of nivolumab in platinum-resistant metastatic/advanced squamous cell carcinomas of the head and neck (SCCHN). We evaluated the outcomes of SCCHN patients in Ontario, Canada, treated with nivolumab through retrospective review of the provincial treatment registry. Kaplan-Meier method was used to estimate overall survival (OS) and Cox regression to evaluate the prognostic effect of selected factors. Nivolumab was used as second-line therapy after disease relapse for curative-intent platinum chemotherapy (PC) (indication 1-I1), as second-line therapy post-PC in noncurative intent (indication 2-I2), and as first-line therapy in noncurative intent due to contraindication for PC (indication 3-I3)...
January 17, 2024: Journal of Immunotherapy
https://read.qxmd.com/read/38205349/pd-1-checkmate-and-the-2-edged-sword-of-the-immune-system-what-next
#24
EDITORIAL
Madeleine W Cunningham, Leslie T Cooper
No abstract text is available yet for this article.
December 2023: JACC. Basic to Translational Science
https://read.qxmd.com/read/38179060/notch-activation-defines-immune-suppressive-subsets-of-ccrccs-with-unfavorable-benefits-from-immunotherapy-over-vegfr-mtor-inhibitors
#25
JOURNAL ARTICLE
Sujun Han, Yu Xu, Dong Chen, Feiya Yang, Mingshuai Wang, Qiaoxia Zhou, Guoqiang Wang, Leo Li, Chunwei Xu, Wenxian Wang, Shangli Cai, Nianzeng Xing
The evolutionarily conserved Notch pathway, involved in cancer stem cell capacity and cancer immunity, may predict the benefit from immune checkpoint inhibitors (ICIs) in clear cell renal cell carcinoma (ccRCC). In the TCGA dataset, mRNA expression of Notch pathway genes identified three clusters with different prognoses and molecular characteristics. Based on the differentially expressed Notch pathway genes between clusters, we constructed the Notch-score, correlated with Notch activation, angiogenesis, PI3K-AKT-mTOR activity, and sensitivities to VEGFR/mTOR inhibitors...
January 19, 2024: IScience
https://read.qxmd.com/read/38177857/author-correction-adjuvant-nivolumab-in-resected-stage-iib-c-melanoma-primary-results-from-the-randomized-phase-3-checkmate-76k-trial
#26
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M Meniawy, Paolo A Ascierto, Alexander M Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V Long
No abstract text is available yet for this article.
January 4, 2024: Nature Medicine
https://read.qxmd.com/read/38176992/corrigendum-to-disease-free-survival-analysis-for-patients-with-high-risk-muscle-invasive-urothelial-carcinoma-from-the-randomized-checkmate-274-trial-by-pd-l1-combined-positive-score-and-tumor-cell-score-eur-urol-83-5-2024-432-440
#27
Matthew D Galsky, Dean F Bajorin, Johannes Alfred Witjes, Jürgen E Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P Valderrama, Marc-Oliver Grimm, Leonard Appleman, Gwenaelle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind-Rotolo, Joshua Zhang, Keziban Ünsal-Kaçmaz
No abstract text is available yet for this article.
January 3, 2024: European Urology
https://read.qxmd.com/read/38174143/reflecting-real-world-patients-with-mesothelioma-in-research-an-interim-report-of-baseline-characteristics-from-the-assess-meso-cohort
#28
JOURNAL ARTICLE
Ruairi J H Conway, Natalie Smith, William Cooper, Geraldine Lynch, Sonia Patole, Jenny Symonds, Anthony Edey, Nick A Maskell, Anna C Bibby
OBJECTIVE: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma cohort study (ISRCTN61861764). This pre-specified interim analysis, conducted when recruitment reached 25% of target, summarised participant characteristics and evaluated external validity through comparison with real-world and clinical trial cohorts. METHODS: The study took place at 14 hospitals across the UK...
November 2023: ERJ Open Research
https://read.qxmd.com/read/38172023/first-line-management-of-metastatic-urothelial-cancer-current-and-future-perspectives-after-the-ev-302-and-checkmate-901-studies
#29
JOURNAL ARTICLE
María Dolores Fenor de la Maza, Guillermo Villacampa, Bernardino Miñana, Guillermo Barbas Bernardos, Guillermo Andrés, Daniel Antonio González-Padilla, Fernando Ramón de Fata, Julián Sanz, Mauricio Cambeiro, Javier Aristu, Alfonso Gúrpide, Felipe Villacampa, Jose Luis Pérez Gracia
The standard of care for the first-line management of metastatic urothelial carcinoma has been recently challenged, with the combination of pembrolizumab and enfortumab vedotin (P-EV) strongly arising as a practice-changing option from classical platinum-based chemotherapies. With this paradigm shift on the horizon new questions, including the most suitable second line of treatment for these patients, and the role that the molecular characterization of these tumours will have when selecting these therapies will inevitably arise...
December 13, 2023: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38171116/pd-l1-is-a-biomarker-of-real-world-clinical-outcomes-for-anti-ctla-4-plus-anti-pd-1-or-anti-pd-1-monotherapy-in-metastatic-melanoma
#30
JOURNAL ARTICLE
Eva Ellebaek, Shawez Khan, Lars Bastholt, Henrik Schmidt, Charlotte Aaquist Haslund, Marco Donia, Inge Marie Svane
BACKGROUND: Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression. METHODS: We conducted a population-based study including all patients with MM (except ocular melanoma) treated in Denmark with first-line combination therapy or anti-PD-1 monotherapy since January 2017. Baseline data including known prognostic characteristics were used in multivariable and propensity-matched score (PMS) analyses to assess progression-free survival (PFS), melanoma-specific survival (MSS), and overall survival (OS) according to PD-L1 expression...
February 2024: European Journal of Cancer
https://read.qxmd.com/read/38159967/short-term-outcomes-of-adjuvant-nivolumab-after-neoadjuvant-chemotherapy-in-patients-with-resected-esophageal-squamous-cell-carcinoma
#31
JOURNAL ARTICLE
Takahito Sugase, Takashi Kanemura, Tomohira Takeoka, Norihiro Matsuura, Yasunori Masuike, Naoki Shinno, Hisashi Hara, Masatoshi Kitakaze, Masahiko Kubo, Yosuke Mukai, Toshinori Sueda, Shinichiro Hasegawa, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata
BACKGROUND/AIM: CheckMate 577 evaluated adjuvant nivolumab therapy after neoadjuvant chemoradiotherapy and surgery for esophageal cancers. However, the efficacy of this treatment in patients who received neoadjuvant chemotherapy remains unknown. This study investigated the short-term outcomes of adjuvant nivolumab therapy in patients with advanced esophageal squamous cell carcinoma post-neoadjuvant chemotherapy. PATIENTS AND METHODS: Out of 956 patients with thoracic esophageal cancer who underwent radical esophagectomy, 227 who exhibited ypN1-3 after neoadjuvant chemotherapy and surgery were included in this study...
January 2024: Anticancer Research
https://read.qxmd.com/read/38152696/cxcl14-as-a-potential-marker-for-immunotherapy-response-prediction-in-renal-cell-carcinoma
#32
JOURNAL ARTICLE
Qiwen Pan, Ruiqi Liu, Xinyue Zhang, Lingling Cai, Yilin Li, Pei Dong, Jianming Gao, Yang Liu, Liru He
BACKGROUND: Epigenetic mechanisms play vital roles in the activation, differentiation, and effector function of immune cells. The breast and kidney-expressed chemokine (CXCL14) mainly contributes to the regulation of immune cells. However, its role in shaping the tumor immune microenvironment (TIME) is yet to be elucidated in renal cell carcinoma (RCC). OBJECTIVES: This study aimed to elucidate the role of CXCL14 in predicting the efficacy of immunotherapy in patients with RCC...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38151184/nivolumab-in-sorafenib-naive-and-sorafenib-experienced-patients-with-advanced-hepatocellular-carcinoma-5-year-follow-up-from-checkmate-040
#33
JOURNAL ARTICLE
A B El-Khoueiry, J Trojan, T Meyer, T Yau, I Melero, M Kudo, C Hsu, T-Y Kim, S-P Choo, Y-K Kang, W Yeo, A Chopra, S Soleymani, J Yao, J Neely, M Tschaika, T H Welling, B Sangro
BACKGROUND: Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here. PATIENTS AND METHODS: Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity...
December 25, 2023: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38140246/checkpoint-immunotherapy-in-pediatric-oncology-will-we-say-checkmate-soon
#34
REVIEW
Alexander Ciurej, Elizabeth Lewis, Avanti Gupte, Eman Al-Antary
Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by "turning off the brakes" of effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, their utility in pediatric cancer has not yet been shown to be as fruitful. We review ICIs, their use in pediatric malignancies, and active pediatric clinical trials, exemplifying some of adult efforts that could be related to pediatric future trials and complications of ICI therapy...
December 12, 2023: Vaccines
https://read.qxmd.com/read/38136333/current-state-of-the-art-therapy-for-malignant-pleural-mesothelioma-and-future-options-centered-on-immunotherapy
#35
REVIEW
Susana Cedres, Augusto Valdivia, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Juan David Assaf-Pastrana, Enriqueta Felip, Pilar Garrido
Malignant pleural mesothelioma (MPM) is a locally aggressive disease related to asbestos exposure with a median survival for untreated patients of 4-8 months. The combination of chemotherapy based on platinum and antifolate is the standard treatment, and the addition of bevacizumab adds two months to median survival. Recently, in first-line treatment, immunotherapy combining nivolumab with ipilimumab has been shown to be superior to chemotherapy in the CheckMate-743 study in terms of overall survival (18.1 months), leading to its approval by the FDA and EMA...
December 10, 2023: Cancers
https://read.qxmd.com/read/38136288/claudin18-2-in-advanced-gastric-cancer
#36
REVIEW
Rin Inamoto, Naoki Takahashi, Yasuhide Yamada
Globally, the fifth most common cancer and the fourth leading cause of cancer-related mortality is gastric cancer (GC). Recent clinical trials on solid tumors enrolled patients who possess druggable genetic alterations, protein expression, and immune characteristics. In gastric or gastroesophageal junction (GEJ) cancers, trastuzumab combined with first-line chemotherapy in human epidermal growth factor receptor 2 (HER2)-positive patients and ramucirumab combined with second-line paclitaxel remarkably prolonged overall survival (OS) compared with chemotherapy alone, according to phase 3 trial results...
December 7, 2023: Cancers
https://read.qxmd.com/read/38135212/unanchored-population-adjusted-indirect-comparison-methods-for-time-to-event-outcomes-using-regression-adjustment-inverse-odds-weighting-and-doubly-robust-methods-with-either-individual-patient-or-aggregate-data
#37
JOURNAL ARTICLE
Julie E Park, Harlan Campbell, Kevin Towle, Yong Yuan, Jeroen P Jansen, David Phillippo, Shannon Cope
OBJECTIVES: Several methods for unanchored population-adjusted indirect comparisons (PAIC) are available. Exploring alternative adjustment methods, depending on the individual patient data (IPD) available and the aggregate data (AD) in the external study, may help minimize bias in unanchored indirect comparisons. However, methods for time-to-event outcomes are not well understood. We provide an overview and comparison of methods using a case study to increase familiarity. We apply a recent method to marginalize conditional hazard ratios, which allows for the comparisons of methods, and we propose a doubly robust method...
December 20, 2023: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/38126175/nivolumab-in-unresectable-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma
#38
REVIEW
Go Ikeda, Jun Miyakoshi, Shun Yamamoto, Ken Kato
Esophageal cancer (EC) is the eighth most common cancer worldwide. In view of biology and anatomical restrictions, multimodality treatment strategies have been developed for EC. However, the prognosis of patients with advanced EC remains especially poor. Immunotherapy, such as PD-1/PD-L1 and CTLA-4/B7 blockade, has emerged as a potent treatment for many types of cancer and has been approved in many countries. Based on the results of the ATTRACTION-3 trial, nivolumab, an anti-PD-1 monoclonal antibody, was approved by the US FDA for patients with platinum-resistant, unresectable, recurrent or metastatic esophageal squamous cell carcinoma...
December 21, 2023: Future Oncology
https://read.qxmd.com/read/38115195/model-based-dose-selection-of-subcutaneous-nivolumab-in-patients-with-advanced-solid-tumors
#39
JOURNAL ARTICLE
Yue Zhao, Kinjal Sanghavi, Amit Roy, Bindu Murthy, Akintunde Bello, Urvi Aras, Heather Vezina
The pharmacokinetics (PK) of intravenous (IV) nivolumab is well characterized. A subcutaneous (SC) nivolumab formulation with and without recombinant human hyaluronidase PH20 enzyme is being evaluated in CheckMate 8KX (NCT03656718). A model-based analysis was conducted to characterize the PK of nivolumab SC and predict systemic exposures after IV and SC administration to guide dosing regimen selection for nivolumab SC. A prior IV model was modified to incorporate an SC extravascular compartment and estimate the absorption rate constant (Ka ) and bioavailability (F) of nivolumab SC...
December 19, 2023: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38098509/outcome-and-treatment-related-adverse-events-of-combined-immune-checkpoint-inhibition-with-flipped-dosing-in-a-real-world-cohort-of-79-patients-with-metastasized-melanoma
#40
JOURNAL ARTICLE
Charlotte Nübel, Teresa Amaral, Ulrike Leiter, Lukas Flatz, Andrea Forschner
INTRODUCTION: Combined immune checkpoint inhibition (ICI) with ipilimumab and nivolumab is a widely used treatment regimen for metastatic melanoma with non-resectable metastases. Nevertheless, the standard dose of ipilimumab 3 mg/kg bw and nivolumab 1 mg/kg bw is associated with a high rate of treatment-related adverse events (trAEs) (59% grade 3-4). In the CheckMate 511 study, it could be shown that flipped dosing with ipilimumab 1 mg/kg bw and nivolumab 3 mg/kg bw resulted in a significant reduction of trAE...
2023: Frontiers in Oncology
keyword
keyword
68498
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.